Chronic Lymphocytic Leukemia | Specialty

Next-Generation BTK Inhibitor Taking on Ibrutinib in CLL

December 8th 2015

Acalabrutinib has demonstrated a 95% response rate and durable remissions with a favorable safety profile in a phase I/II study for patients with chronic lymphocytic leukemia.

Ibrutinib Bests Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

December 7th 2015

Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Venetoclax Sparks High Response Rate in Poor-Risk CLL Subtype

December 6th 2015

Venetoclax, demonstrated an overall response rate of nearly 80% among patients with chronic lymphocytic leukemia harboring the chromosome 17p deletion.

Frontline Ibrutinib Significantly Improves Survival in CLL

December 6th 2015

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naïve elderly patients with chronic lymphocytic leukemia.

Idelalisib Triplet Highly Effective for Relapsed/Refractory CLL

December 6th 2015

The addition of idelalisib to bendamustine and rituximab (BR) reduced the risk of progression or death by 67% compared with BR alone for patients with relapsed/refractory chronic lymphocytic leukemia.

Study Suggests Role for CAR Therapy After Transplant in Advanced B-cell Cancers

December 5th 2015

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

Dr. Wierda on Combination Regimens With Venetoclax in CLL

December 4th 2015

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

Novel Agents Increasingly Individualize CLL Care

November 24th 2015

William G. Wierda, MD, PhD, gives a better understanding of the changing landscape of chronic lymphocytic leukemia and how treatment options vary among different patient subtypes.

Novel Agents Offer Promise in CLL, But Challenges Remain

November 17th 2015

Dr. Thomas Kipps discusses how challenges in CLL may be met in the future and the impact obinutuzumab, venetoclax, and other novel agents could have on CLL treatment.

Positive Interim Analysis Halts Phase III Idelalisib CLL Study

November 16th 2015

A phase III study exploring idelalisib in combination with bendamustine and rituximab for patients with previously treated chronic lymphocytic leukemia has been stopped early following a positive interim analysis.

Label Update Sought for Ibrutinib in CLL

November 13th 2015

A supplemental new drug application has been submitted for ibrutinib (Imbruvica) for use in combination with bendamustine and rituximab to treat patients with relapsed or refractory chronic lymphocytic leukemia.

New Blood Cancer Landscape Taking Shape

November 12th 2015

Experts discuss developments in CLL, myeloma, and Hodgkin lymphoma.

B-cell Pathway Inhibitors Show Clear Benefit in CLL

November 4th 2015

B-cell pathway inhibitors have shown impressive survival benefits for patients with chronic lymphocytic leukemia, but require careful monitoring and possible suspension to control adverse events.

Anti-CD20 Antibodies Effective in Elderly CLL Patients

October 27th 2015

Alessandra Ferrajoli, MD, discusses the impact of the CLL11 and COMPLEMENT 1 trials, as well as other treatments that may be beneficial to the elderly chronic lymphocytic leukemia population.

Potential Driver Mutations Identified in CLL

October 27th 2015

Dozens of genetic abnormalities, including 44 mutated genes and 11 recurrent somatic copy number variations, were found to potentially play a role in progression and/or relapse of chronic lymphocytic leukemia.

Dr. Ferrajoli on Treatment of Elderly Patients With CLL

October 22nd 2015

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Emerging Treatments for Chronic Lymphocytic Leukemia

October 20th 2015

Utilizing Maintenance Therapy for Chronic Lymphocytic Leukemia

October 20th 2015

Therapeutic Combinations and Sequences for CLL

October 20th 2015